451
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Descriptor analysis of estrogen receptor β-selective ligands using 2-phenylquinoline, tetrahydrofluorenone and 3-hydroxy 6H-benzo[c]chromen-6-one scaffolds

, , , &
Pages 831-842 | Received 06 Mar 2010, Accepted 19 Feb 2011, Published online: 25 Mar 2011

Figures & data

Table 1.  Structural features, observed and predicted ERβ IC50 values and ERα/β fold selectivity for 2-phenylquinoline scaffold.

Table 2.  Structural features, observed and predicted ERβ IC50 values and ERα/β fold selectivity for tetrahydrofluorenone scaffold.

Table 3.  Structural features, observed and predicted values for ERβ IC50 values and ERα/β fold selectivity for 3-hydroxy- 6H-benzo[c]chromen-6-one scaffold.

Table 4.  Molecular descriptors selected for the study.

Table 5.  Physicochemical descriptors that significantly influenced the 2-phenylquinoline derivatives binding at ER receptors.

Figure 1.  Skeletal structure of estrogenic compounds. The moieties derivatised in each compound is indicated and referred in the , , and .

Figure 1.  Skeletal structure of estrogenic compounds. The moieties derivatised in each compound is indicated and referred in the Tables 1, 2, and 3.

Table 6.  QSAR statistics of the best multiple linear regression equations.

Figure 2.  Plot of predicted vs. observed values of ERβ binding affinity and fold selectivity of the ligands against ER receptors. (A), (C) and (E) represent the ERβ binding affinity of phenylquinoline, tetrahydrofluorenone and 3-hydroxy 6H-benzo[c]chromen-6-one ligands respectively. (B), (D) and (F) represent the ERβ fold selectivity of phenylquinoline, tetrahydrofluorenone and 3-hydroxy 6H-benzo[c]chromen-6-one ligands, respectively.

Figure 2.  Plot of predicted vs. observed values of ERβ binding affinity and fold selectivity of the ligands against ER receptors. (A), (C) and (E) represent the ERβ binding affinity of phenylquinoline, tetrahydrofluorenone and 3-hydroxy 6H-benzo[c]chromen-6-one ligands respectively. (B), (D) and (F) represent the ERβ fold selectivity of phenylquinoline, tetrahydrofluorenone and 3-hydroxy 6H-benzo[c]chromen-6-one ligands, respectively.

Figure 3.  (A) Docked pose of most active compound 7 (green) and least active compound 21 (grey) in the phenylquinoline series with ERβ. Only key residues (pink), of the ERβ binding site are shown for simplicity. (B) Docked pose of most active compound 28 (green) and least active compound 7 (grey) in the tetrahydrofluorenone series with ERβ. Only key residues (pink), of the ERβ binding site are shown for simplicity. (C) Docked pose of most active compound 23 (green) and least active compound 7 (grey) in the tetrahydrofluorenone series with ERβ. Only key residues (pink), of the ERβ binding site are shown for simplicity.

Figure 3.  (A) Docked pose of most active compound 7 (green) and least active compound 21 (grey) in the phenylquinoline series with ERβ. Only key residues (pink), of the ERβ binding site are shown for simplicity. (B) Docked pose of most active compound 28 (green) and least active compound 7 (grey) in the tetrahydrofluorenone series with ERβ. Only key residues (pink), of the ERβ binding site are shown for simplicity. (C) Docked pose of most active compound 23 (green) and least active compound 7 (grey) in the tetrahydrofluorenone series with ERβ. Only key residues (pink), of the ERβ binding site are shown for simplicity.

Table 7.  Physicochemical descriptors that significantly influenced the tetrahydrofluorenone derivatives binding at ER receptors.

Table 8.  Physicochemical descriptors that significantly influenced the 3-hydroxy 6H-benzo[c]chromen-6-one derivatives binding at ER receptors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.